CarlosDeCastroMD

PubMed

• 1398 citations
  Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
  Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland
  Journal of Clinical Oncology. 2002-05-15
• 326 citations
  Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study
  Alice B. Kornblith, James E. Herndon, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig
  Journal of Clinical Oncology. 2002-05-15
• 24 citations
  Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia
  David A. Rizzieri, Jenny A. O'Brien, Gloria Broadwater, Carlos M. DeCastro, Prakash Dev
  Cancer. 2009-07-01

Journal Articles

• A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy  
  Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE, American Journal of Hematology, 1/1/2015
• Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria  
  Hillmen P, Muus P, Roth A, Elebute MO, Risitanon AM, Schrezenmeter H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socie G, Brodsky RA, Brit J Haematol, 1/1/2013
• Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia  
  Morris TA. DeCastro CM. Diehl LF. Gockerman JP. Lagoo AS. Li Z. Moore JO. Rizzieri DA. Rao AV, Leukemia Research, 1/1/2013
• A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma  
  Held LA. Rizzieri D. Long GD. Gockerman JP. Diehl LF. de Castro CM. Moore JO. Horwitz ME. Chao NJ. Gasparetto C, Cancer Investigation, 1/1/2013
• Myelodysplastic Syndromes: clinical practice guidelines in oncology  
  Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Mi..., Journal of the National Comprehensive Cancer Network, 1/1/2013
• Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia  
  Lanasa MC. Davis PH. Datto M. Li Z. Gockerman JP. Moore JO. DeCastro CM. Friedman DR. Diehl LF. Rehder C. Cook H. Daugherty FJ. Matta KM. Weinberg JB. Rizzieri D, Leukemia & Lymphoma, 1/1/2012
• Too many clots for comfort  
  Mohanty BD. De Castro CM, American Journal of Medicine, 1/1/2012
• NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes  
  Greenberg PL. Attar E. Bennett JM. Bloomfield CD. De Castro CM. Deeg HJ. Foran JM. Gaensler K. Garcia-Manero G. Gore SD. Head D. Komrokji R. Maness LJ. Millenson M. Ni..., Journal of the National Comprehensive Cancer Network, 1/1/2011
• SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target  
  Christensen DJ. Chen Y. Oddo J. Matta KM. Neil J. Davis ED. Volkheimer AD. Lanasa MC. Friedman DR. Goodman BK. Gockerman JP. Diehl LF. de Castro CM. Moore JO. Vitek MP..., Blood, 1/1/2011
• A Phase II trial of gemcitabine and mitoxantrone in patients with acute myeloid leukemia in first relapse  
  Advani AS, Shadman M, Ali-Osman F, Barker A, Rybicki L, Kalaycio M, Sekeres MA, de Castro CM, Diehl LF, Moore JO, Beaven A, Copelan E, Sobecks R, Talea P, Rizzieri DA, Clinical lymphoma, myeloma, and leukemia, 1/1/2010
• The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function  
  Dimopoulos M. Alegre A. Stadtmauer EA. Goldschmidt H. Zonder JA. de Castro CM. Masliak Z. Reece D. Olesnyckyj M. Yu Z. Weber DM, Cancer, 1/1/2010
• Short course- bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previousl...  
  Gasparetto C. Gockerman JP. Diehl LF. De Castro CM. Moore JO. Long GD. Horwitz ME. Keogh G. Chute JP. Sullivan KM. Neuwirth R. Davis PH. Sutton LM. Anderson RD. Chao N..., Biol Blood Marrow Transplant, 1/1/2010
• Treatment of Myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)  
  Grinblatt DL. Yu D. Hars V. Vardimann JW. Powell BL. Nattam S. Silverman LR. De Castro C. Stone RM. Bloomfield CD. Larson RA, Cancer, 1/1/2009
• A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia  
  Friedman DR. Weinberg JB. Barry WT. Goodman BK. Volkheimer AD. Bond KM. Chen Y. Jiang N. Moore JO. Gockerman JP. Diehl LF. DeCastro CM. Potti A. Nevins JR, Clinical Cancer Res, 1/1/2009
• Estimation of economic costs associated with transfusion dependence in adults with MDS  
  Frytak JR. Henk HJ. De Castro CM. Halpern R. Nelson M, Current Medical Research & Opinion, 1/1/2009
• Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia  
  Rao AV. Younis IR. Sand GJ. Spasojevic I. Adams DJ. DeCastro CM. Gockerman JP. Peterson BL. Petros WP. Moore JO. Rizzieri DA, Leukemia & Lymphoma, 1/1/2008
• Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia  
  Weinberg JB. Volkheimer AD. Mihovilovic M. Jiang N. Chen Y. Bond K. Moore JO. Gockerman JP. Diehl LF. De Castro CM. Rizzieri DA. Levesque MC. Dekroon R. Strittatter WJ, Leukemia, 1/1/2008
• Myelodysplastic syndromes  
  Greenberg PL. Attar E. Battiwalla M. Bennett JM. Bloomfield CD. De Castro CM. Deeg HJ. Erba HP. Foran JM. Garcia-Manero G. Gore SD. Head D. Maness LJ. Millenson M. Nim..., Journal of the National Comprehensive Cancer Network, 1/1/2008
• Multicenter phase 3 study of the complement inhibitor Eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria  
  Brodsky RA. Young NS. Antonioli E. Ristano AM. Schrezenmeier H. Schubert J. Gaya A. Coyle L. De Castro C. Fu CL. Maciejewski JP. Bessler M. Kroon HA. Rother RP. Hillmen P, Blood, 1/1/2008
• National Comprehensive Cancer Network (NCCN) Multiple myeloma Clinical practice guidelines in oncology  
  Anderson KC. Alsina M. Bensinger W. Biermann JS. Chanan-Khan A. Comenzo RL. De Castro CM. Djulbegovic B. Farag S. Huff CA. Meredith R. Schriber J. Shrieve D. Singhal S..., Journal of the National Comprehensive Cancer Network, 1/1/2007
• Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution  
  Rizzieri DA. Koh LP. Long GD. Gasparetto C. Sullivan KM. Horwitz M. Chute J. Smith C. Gong JZ. Lagoo A. Niedzwiecki D. Dowell JM. Waters-Pick B. Liu C. Marshall D. Vre..., Journal of Clinical Oncology, 1/1/2007
• Hairy cell leukemia: an elusive but treatable disease  
  Wanko SO. DeCastro C, Oncologist, 1/1/2006
• Myelodysplastic syndromes clinical practice guidelines in oncology  
  Greenberg PL. Baer MR. Bennett JM. Bloomfield CD. De Castro CM. Deeg HJ. Devetten MP. Emanuel PD. Erba HP. Estey E. Foran J. Gore SD. Millenson M. Navarro WH. Nimer SD..., Journal of the National Comprehensive Cancer Network, 1/1/2006
• Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study  
  Kantarjian H. Issa JP. Rosenfeld CS. Bennett JM. Albitar M. DiPersio J. Klimek V. Slack J. de Castro C. Ravandi F. Helmer R 3rd. Shen L. Nimer SD. Leavitt R. Raza A. S..., Cancer, 1/1/2006
• Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and in Japan  
  Nishimura J-I, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, DeCastro CM, Hall S, Kanamaru A, Sullivan KM, Mizoguchi H, Omine M, Kinoshita T, Rosse WF, Medicine, 1/1/2004
• Join now to see all

Abstracts/Posters

• A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes.
  de Castro C, Adams D, Rizzieri D, Moore J, Gockerman J, Diehl L, Horwitz M, Edmonds E, Warzecho J, Leukemia Research, 1/1/2009
• A phase II pilot stury of sorafenib in patients with myelodysplastic syndromes.
  de Castro C, Adams D, Rizzieri D, Moore J, Gockerman J, Diehl L, Horwitz M, Edmonds E, Warzecho J, Leukemia Research, 1/1/2009
• Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.
  Lancet JE, Komrokji RS, Lin HY, de Castro CM, Rizzieri DA , Melchert M, List AF, Blood, 1/1/2009
• The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.
  Christensen DJ, Bond KM, Volkheimer AD, Oddo J, Chen Y, Gockerman JP, Moore JO, Diehl LF, de Castro CM, Vitek MP, Weinberg JB, Blood, 1/1/2009
• Apolipoprotein E (APOE) genotype as a determinant of survival in women with chronic lymphocytic leukemia.
  Weinberg JB. Volkheimer AD. Mihovilovic M. Jiang N. Chen Y. Moore JO. Gockerman JP. Diehl LF. De Castro CM. Rizzieri DA. Leveaque MC. DeKroon R. Strittmatter WJ, Blood, 1/1/2007
• Cytotoxicity of the type 4 phosphodiesterase inhibitor CD160130 for freshly isolated human CLL cells in vitro.
  Weinberg JB. Jiang N. Volkheimer AD. Chen Y. Bond KM. Moore JO. Gockerman JP. DiehlLF. De Castro CM. Rizzieri DA. Levesque MC. Mugridge K. DeAngelo J, Blood, 1/1/2007
• A genomic strategy to refine prognosis and predict response to therapy in chronic lymphocytic leukemia.
  Friedman DR. Weinberg JB. Potti A. Volkheimer AD. Bond KM. Chen Y. Jiang N. Moore JO. Gockerman JP. Diehl LF. deCastro CM. Nevins JR, Blood, 1/1/2007
• MicroRNA expression in red blood cells from patients with PNH.
  Chi J-TA. Sangokoya C. de Castro CM, Blood, 1/1/2007
• Safety and efficacy of the terminal complement inhibitor Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: Interim Shepherd Phase III clinical study.
  Young NS, Antonioli E, Rotoli B, Schrezenmeier H, Schubert J, Urbano-Ispizua A, Coyle L, de Castro C, Fu C-L, Maciejewski JP, Mojcik CF, Rother RP, Hillmen P, Blood, 1/1/2006
• Response rates using International Working Group (IWG) criteria in patients with myelodysplastic syndrome (MDS) treated with azacitidine.
  Silverman LR, McKenzie DR, Peterson BL, De Castro CM, Ellerton J, Knapp KN, Beach CL, Larson RA, Blood, 1/1/2005
• A prospective study of Bortezomib in combination with melphalan and prednisone for patients with previously untreated multiple myeloma.
  Gasparetto C, Keough GP, Gockerman JP, Horwitz M, Moore JO, DeCastroC, Diehl L, Davis P, Chao N, Rizzieri DA, Blood, 1/1/2005
• Feasibility study of a dose dense induction regimen of high dose cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg) for newly diagnosed elderly patients with acut...
  Rao AV, Rizzieri DA, Moore JO, DeCastro C, Diehl LF, AbernethyAP, Jordan M, Davis P, Edmonds E, Gockerman JP, Blood, 1/1/2005
• Predictors of survival in CLL: Multivariate analyses reveal significant correlation with IgVH gene mutation status, clinical stage, and cellular CD38 (but not Zap-70) ...
  Volkheimer AD, Levesque MC, Beasley BE, Diehl L, Chen Y, Vacarro G, DeCastro C, Rizzieri D, Gockerman JP, Moore JO, Weinberg JB, Blood, 1/1/2005
• Economic burden of transfusion dependence in patients with Myelodysplastic syndrome.
  Frytak JR, Henk H, Nelson M, DeCastro C, J Clin Oncol, 1/1/2005
• Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndromes (...
  Saba HI, Rosenfeld CS, Issa JP, Bennett JM, DeCastro C, Dipersio J, Kantarjian H, J Clin Oncol, 1/1/2005
• Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.
  Wanko SO, Gockerman JP, Moore JO, DeCastro C, Prosnitz R, Gasparetto C, Chute J, Horwitz M, Ashley M, Edmonds E, Davis P, Chao NJ, Rizzieri DA, Blood, 1/1/2004
• First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome.
  Saba H, Rosenfeld C, Issa J-P, DiPersio J, Raza A, Klimek V, Slack J, de Castro C, Mettinger K, Kantarjian H, Blood, 1/1/2004
• Dose Dense, High Intensity Therapy in Newly Diagnosed Elderly Patients with Acute Myeloid Leucemia Using Gemtuzumab Ozogamicin (Mylotarg) and High Dose Cytarabine (Hi...
  Rao AV, Rizzieri DA, Moore JO, de Castro CM, Abernethy AP, Jordan M, Davis P, Edmonds E, Gockerman JP, Blood, 1/1/2004
• The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia (AML).
  Misra D, Frankel A, Hall P, Liu TF, Black J, Moore JO, deCastro C, Gockerman JP, Gasparetto C, Horwitz M, davis P, Chao NJ, Rizzieri DA, Blood, 1/1/2004
• Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Mantle C...
  Koh L-P, Gockerman JP, Moore JO, DeCastroC, Long GD, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Lassiter M, Loftis J, Davis P, C..., Blood, 1/1/2004
• Campath-1H May Have Activity in the Treatment of Multiple Myeloma.
  Gasparetto C, Horwitz ME, Gockerman JP, de Castro CM, Moore JO, Smith CA, Davis P, Lassiter M, Houser L, Chao NJ, Rizzieri DA, Blood, 1/1/2004
• Low-dose weekly Paclitaxel for relapsed or refractory aggressive non-Hodgkins lymphoma.
  Rizzieri DA, Sand GJ, McGaughey D, Moore J, DeCastro C, Chao N, Vrendenburgh J, Gasparetto C, Anderson L, Foster T, Niedzwiecki D, Gockerman J, Blood, 1/1/2003
• Phase I trial with pharmacokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma.
  Rizzieri DA, Akabani G, Zalutsky M, Coleman RE, Toaso B, Anderson E, Lagoo A, Clayton S, Niedzwiecki D, Moore JO, Gockerman JP, De Castro C, Chao NJ, Gasparetto C, Big..., Blood, 1/1/2003
• Delayed Transfusion Reactions and Allo- and AutoantibodyProduction in Sickle Cell Patients following Erythrocytapheresis.
  Combs MR, DeCastro CM, Telen MJ, AABB, 1/1/2002
• Low dose, weekly Paclitaxel as salvage therapy for non-Hodgkins lymphoma (NHL).
  Rizzieri DA, de Castro C, Gockerman JP Niedzwiecki D, Vrendenbergh JJ, Gasparetto C, Long G, Payne N, Ibom V, Chao NJ, Moore JO, Blood, 1/1/2001
• Join now to see all

Lectures

• Paroxysmal Nocturnal Hemoglobinuria- Lessons from a Rare Disease 
  Moffitt Cancer Center, Tampa, FL - 1/21/2009
• Visiting Professorship Lectures for Hematology/Oncology Fellows: MDS 
  University of Florida College of Medicine, Gainsville, FL - 1/19/2009
• Epigenetic Therapy for Myelodysplastic Syndromes 
  Shanghai, China - 1/18/2009
• The PNH disease awareness pathway 
  Stockholm, Sweden - 1/11/2009
• Diagnosis and Treatment of PNH 
  Medical College of Georgia, Augusta, GA - 1/10/2009
• Complications of PNH and Treatments 
  Indianapolis, IN - 1/9/2009
• PNH Case Presentations 
  Indianapolis, IN - 1/9/2009
• PNH-101: Basics of PNH 
  Indianapolis, IN - 1/9/2009
• Paroxysmal Nocturnal Hemoglobinuria - Lessons from a Rare Disease 
  Medical University of South Carolina, Charleston, SC - 1/6/2009
• Myelodysplastic Syndromes 
  Concord Medical Center, Concord, NC - 1/29/2008
• Newer Treatments for PNH and MDS 
  Good Samaritan Medical Center, West Palm Beach, FL - 1/24/2008
• Case Studies in Myelodysplastic Syndromes 
  Philadelphia, PA - 1/14/2008
• Diagnosing and Treating PNH 
  Fox Chase Cancer Center, Philadelphia, PA - 1/12/2008
• Recent Updates in Myelodysplastic Syndromes 
  Myrtle Beach, SC - 1/12/2008
• An Update on Recognizing, Diagnosing, and Treatment of PNH 
  San Juan VA Hospital, San Juan, Puerto Rico; San Juan Municipal Hospital, San Juan, Puerto Rico - 1/2/2008
• Paroxysmal Nocturnal Hemoglobinuria – Lessons from a Rare Disease 
  Duke University Medical Center, Durham, NC - 1/1/2008
• Introduction to epigenetic therapy in MDS 
  Fortaleza, Brazil - 1/28/2007
• MDS treatment with decitabine 
  Fortaleza, Brazil - 1/28/2007
• Clinical use of decitabine in the treatment of MDS 
  Moscow, Russia - 1/24/2007
• Epigenetic Therapy for Myelodysplatic Syndromes 
  Duke University Medical Center, Durham, NC - 1/21/2007
• Epigenetic Therapy, Future treatments of MDS 
  Buenos Aires, Argentina - 1/13/2007
• Epigenetic therapy of elderly patients with MDS: a US perspective 
  Orlando, FL - 1/8/2006
• Join now to see all